Search research articles
Contact Us
Filters
Showing results (31-40 of 55) with videos related to
Page
of 6
Sort By:
British Journal of Haematology
|
May 7, 2026
A dexamethasone-free daratumumab-ixazomib regimen in frail elderly patients with relapsed or refractory multiple myeloma: Results of the IFM 2018-02 phase II study
Arthur Bobin, Margaret Macro, Cyrille Touzeau, et al.
Leukemia Research
|
January 15, 2008
Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide
C Kelaidi, S Park, S Brechignac, et al.
Haematologica
|
May 7, 2011
Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA
Olivier Fitoussi, Karim Belhadj, Nicolas Mounier, et al.
Haematologica
|
December 18, 2009
Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des Myelodysplasies
Charikleia Kelaidi, Aspasia Stamatoullas, Odile Beyne-Rauzy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 7, 2022
In Multiple Myeloma, High-Risk Secondary Genetic Events Observed at Relapse Are Present From Diagnosis in Tiny, Undetectable Subclonal Populations
Romain Lannes, Mehmet Samur, Aurore Perrot, et al.
Journal of Geriatric Oncology
|
June 28, 2015
Autologous hematopoietic stem cell transplantation in elderly patients (≥ 70 years) with non-Hodgkin's lymphoma: A French Society of Bone Marrow Transplantation and Cellular Therapy retrospective study
E Hermet, A Cabrespine, R Guièze, et al.
Blood Cancer Journal
|
October 25, 2023
Prognostic impact of translocation t(14;16) in multiple myeloma according to the presence of additional genetic lesions
Anaïs Schavgoulidze, Aurore Perrot, Titouan Cazaubiel, et al.
Blood
|
October 20, 2020
del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma
Jill Corre, Aurore Perrot, Denis Caillot, et al.
Leukemia
|
June 8, 2021
Improved survival in multiple myeloma during the 2005-2009 and 2010-2014 periods
Jill Corre, Aurore Perrot, Cyrille Hulin, et al.
Blood
|
November 14, 2022
Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor
Anaïs Schavgoulidze, Alexis Talbot, Aurore Perrot, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 55) with videos related to
Sort By:
Page
of 6
British Journal of Haematology
|
May 7, 2026
A dexamethasone-free daratumumab-ixazomib regimen in frail elderly patients with relapsed or refractory multiple myeloma: Results of the IFM 2018-02 phase II study
Arthur Bobin, Margaret Macro, Cyrille Touzeau, et al.
Leukemia Research
|
January 15, 2008
Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide
C Kelaidi, S Park, S Brechignac, et al.
Haematologica
|
May 7, 2011
Survival impact of rituximab combined with ACVBP and upfront consolidation autotransplantation in high-risk diffuse large B-cell lymphoma for GELA
Olivier Fitoussi, Karim Belhadj, Nicolas Mounier, et al.
Haematologica
|
December 18, 2009
Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des Myelodysplasies
Charikleia Kelaidi, Aspasia Stamatoullas, Odile Beyne-Rauzy, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 7, 2022
In Multiple Myeloma, High-Risk Secondary Genetic Events Observed at Relapse Are Present From Diagnosis in Tiny, Undetectable Subclonal Populations
Romain Lannes, Mehmet Samur, Aurore Perrot, et al.
Journal of Geriatric Oncology
|
June 28, 2015
Autologous hematopoietic stem cell transplantation in elderly patients (≥ 70 years) with non-Hodgkin's lymphoma: A French Society of Bone Marrow Transplantation and Cellular Therapy retrospective study
E Hermet, A Cabrespine, R Guièze, et al.
Blood Cancer Journal
|
October 25, 2023
Prognostic impact of translocation t(14;16) in multiple myeloma according to the presence of additional genetic lesions
Anaïs Schavgoulidze, Aurore Perrot, Titouan Cazaubiel, et al.
Blood
|
October 20, 2020
del(17p) without TP53 mutation confers a poor prognosis in intensively treated newly diagnosed patients with multiple myeloma
Jill Corre, Aurore Perrot, Denis Caillot, et al.
Leukemia
|
June 8, 2021
Improved survival in multiple myeloma during the 2005-2009 and 2010-2014 periods
Jill Corre, Aurore Perrot, Cyrille Hulin, et al.
Blood
|
November 14, 2022
Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor
Anaïs Schavgoulidze, Alexis Talbot, Aurore Perrot, et al.
Page
of 6